Since differentially methylated insulin gene is recently detected as biomarker of progressive beta cell loss, the discovery of novel blood-based epigenetic biomarkers may be used to predict risk for diabetes development and development of its related complications. This evidence concerns the gene INS and diabetes mellitus.